HUE030839T2 - Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol - Google Patents

Info

Publication number

HUE030839T2

HUE030839T2 HUE05752122A HUE05752122A HUE030839T2 HU E030839 T2 HUE030839 T2 HU E030839T2 HU E05752122 A HUE05752122 A HU E05752122A HU E05752122 A HUE05752122 A HU E05752122A HU E030839 T2 HUE030839 T2 HU E030839T2

Authority

HU

Hungary

Prior art keywords

compound

quinazolin

phenyl

ylamino

purin

Prior art date

2004-05-13

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title abstract description 56
• 108091007960 PI3Ks Proteins 0.000 title abstract description 29
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title abstract description 29
• 239000003112 inhibitor Substances 0.000 title description 73
• AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title description 4
• 150000001875 compounds Chemical class 0.000 abstract description 561
• 238000000034 method Methods 0.000 abstract description 344
• 230000000694 effects Effects 0.000 abstract description 112
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 56
• 230000002401 inhibitory effect Effects 0.000 abstract description 38
• 210000000265 leukocyte Anatomy 0.000 abstract description 34
• 208000035475 disorder Diseases 0.000 abstract description 29
• 201000010099 disease Diseases 0.000 abstract description 27
• 108010029485 Protein Isoforms Proteins 0.000 abstract description 20
• 102000001708 Protein Isoforms Human genes 0.000 abstract description 20
• 230000004054 inflammatory process Effects 0.000 abstract description 18
• 206010061218 Inflammation Diseases 0.000 abstract description 16
• 230000036039 immunity Effects 0.000 abstract description 7
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 122
• 210000004027 cell Anatomy 0.000 description 102
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 87
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 82
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 80
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 77
• 229940126543 compound 14 Drugs 0.000 description 77
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
• 210000000440 neutrophil Anatomy 0.000 description 72
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 65
• 239000000203 mixture Substances 0.000 description 60
• 238000006243 chemical reaction Methods 0.000 description 58
• 239000000243 solution Substances 0.000 description 58
• 230000006870 function Effects 0.000 description 57
• CTGFGRDVWBZYNB-UHFFFAOYSA-N 6-bromo-7h-purine Chemical compound BrC1=NC=NC2=C1NC=N2 CTGFGRDVWBZYNB-UHFFFAOYSA-N 0.000 description 56
• 238000010511 deprotection reaction Methods 0.000 description 55
• 239000011541 reaction mixture Substances 0.000 description 48
• 239000007787 solid Substances 0.000 description 48
• URUMIJQEKNQEHN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(phenylmethoxycarbonylamino)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)C(CC)NC(=O)OCC1=CC=CC=C1 URUMIJQEKNQEHN-UHFFFAOYSA-N 0.000 description 47
• 108090000765 processed proteins & peptides Proteins 0.000 description 45
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
• 102000004196 processed proteins & peptides Human genes 0.000 description 41
• -1 phosphatidylinositol lipids Chemical class 0.000 description 40
• HPGBGNVPUMCKPM-UHFFFAOYSA-N 6-bromo-7h-purin-2-amine Chemical compound NC1=NC(Br)=C2NC=NC2=N1 HPGBGNVPUMCKPM-UHFFFAOYSA-N 0.000 description 36
• 229920001184 polypeptide Polymers 0.000 description 36
• 239000000543 intermediate Substances 0.000 description 35
• 238000005160 1H NMR spectroscopy Methods 0.000 description 34
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
• 238000002360 preparation method Methods 0.000 description 34
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 33
• 229940095574 propionic acid Drugs 0.000 description 33
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 31
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
• 210000003719 b-lymphocyte Anatomy 0.000 description 30
• 239000001257 hydrogen Substances 0.000 description 30
• 229910052739 hydrogen Inorganic materials 0.000 description 30
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 29
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
• 102000038030 PI3Ks Human genes 0.000 description 27
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
• 235000019439 ethyl acetate Nutrition 0.000 description 26
• 210000001519 tissue Anatomy 0.000 description 26
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
• 239000000706 filtrate Substances 0.000 description 25
• 238000012360 testing method Methods 0.000 description 25
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 24
• 150000003839 salts Chemical class 0.000 description 23
• 230000002829 reductive effect Effects 0.000 description 22
• 102000004190 Enzymes Human genes 0.000 description 21
• 108090000790 Enzymes Proteins 0.000 description 21
• 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 21
• 238000003556 assay Methods 0.000 description 21
• 239000008194 pharmaceutical composition Substances 0.000 description 21
• 239000000047 product Substances 0.000 description 21
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 20
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
• 150000002431 hydrogen Chemical class 0.000 description 20
• 230000005764 inhibitory process Effects 0.000 description 20
• 238000010992 reflux Methods 0.000 description 20
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
• 108090000623 proteins and genes Proteins 0.000 description 19
• 239000000725 suspension Substances 0.000 description 19
• 206010028980 Neoplasm Diseases 0.000 description 18
• 230000001404 mediated effect Effects 0.000 description 18
• 229910052757 nitrogen Inorganic materials 0.000 description 18
• 239000002253 acid Substances 0.000 description 17
• 239000003795 chemical substances by application Substances 0.000 description 17
• 238000003756 stirring Methods 0.000 description 17
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
• 238000004440 column chromatography Methods 0.000 description 16
• 238000003818 flash chromatography Methods 0.000 description 16
• 210000002997 osteoclast Anatomy 0.000 description 16
• 229910000027 potassium carbonate Inorganic materials 0.000 description 16
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
• 230000004913 activation Effects 0.000 description 15
• 102000004169 proteins and genes Human genes 0.000 description 15
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
• 241001465754 Metazoa Species 0.000 description 14
• 210000001744 T-lymphocyte Anatomy 0.000 description 14
• 125000005843 halogen group Chemical group 0.000 description 14
• 230000005012 migration Effects 0.000 description 14
• 238000013508 migration Methods 0.000 description 14
• 238000000746 purification Methods 0.000 description 14
• SKAPFLYTJSVTBF-UHFFFAOYSA-N 2-amino-6-(morpholin-4-ylmethyl)-n-phenylbenzamide Chemical compound C=1C=CC=CC=1NC(=O)C=1C(N)=CC=CC=1CN1CCOCC1 SKAPFLYTJSVTBF-UHFFFAOYSA-N 0.000 description 13
• XHYVBIXKORFHFM-UHFFFAOYSA-N 2-amino-6-methylbenzoic acid Chemical compound CC1=CC=CC(N)=C1C(O)=O XHYVBIXKORFHFM-UHFFFAOYSA-N 0.000 description 13
• QPXQAORPKBMOCM-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(O)=C1 QPXQAORPKBMOCM-UHFFFAOYSA-N 0.000 description 13
• 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 13
• 210000003651 basophil Anatomy 0.000 description 13
• 201000011510 cancer Diseases 0.000 description 13
• PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 13
• 230000035755 proliferation Effects 0.000 description 13
• 230000004044 response Effects 0.000 description 13
• GAEXVVSRJAUEMH-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]but-3-ynyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(CC#C)NC=2C=3N=CNC=3N=C(N)N=2)N1C1=CC=CC=C1 GAEXVVSRJAUEMH-UHFFFAOYSA-N 0.000 description 12
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 238000007792 addition Methods 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 230000001105 regulatory effect Effects 0.000 description 12
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
• 108010044467 Isoenzymes Proteins 0.000 description 11
• 229940124639 Selective inhibitor Drugs 0.000 description 11
• 230000003197 catalytic effect Effects 0.000 description 11
• 230000028023 exocytosis Effects 0.000 description 11
• 238000000338 in vitro Methods 0.000 description 11
• 208000028867 ischemia Diseases 0.000 description 11
• 229910052938 sodium sulfate Inorganic materials 0.000 description 11
• 235000011152 sodium sulphate Nutrition 0.000 description 11
• COMUWNFVTWKSDT-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)ON1C(=O)CCC1=O COMUWNFVTWKSDT-UHFFFAOYSA-N 0.000 description 10
• MPDZCNPDHUUPRL-UHFFFAOYSA-N 2-fluoro-6-nitrobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1[N+]([O-])=O MPDZCNPDHUUPRL-UHFFFAOYSA-N 0.000 description 10
• JZWCJFFNMSCOBE-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-5-methyl-2-[1-[[9-(2-trimethylsilylethoxymethyl)purin-6-yl]amino]ethyl]quinazolin-4-one Chemical compound N=1C=NC=2N(COCC[Si](C)(C)C)C=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(O)=C1 JZWCJFFNMSCOBE-UHFFFAOYSA-N 0.000 description 10
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
• 229960001340 histamine Drugs 0.000 description 10
• 208000027866 inflammatory disease Diseases 0.000 description 10
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
• 239000006188 syrup Substances 0.000 description 10
• 235000020357 syrup Nutrition 0.000 description 10
• CUEIRRVSBRUWIK-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3-hydroxyphenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(O)=C1 CUEIRRVSBRUWIK-UHFFFAOYSA-N 0.000 description 9
• QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 9
• 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 230000006378 damage Effects 0.000 description 9
• 239000000284 extract Substances 0.000 description 9
• 239000012634 fragment Substances 0.000 description 9
• 239000003921 oil Substances 0.000 description 9
• 239000012044 organic layer Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 239000013598 vector Substances 0.000 description 9
• QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 9
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 8
• CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 8
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
• 102000016387 Pancreatic elastase Human genes 0.000 description 8
• 108010067372 Pancreatic elastase Proteins 0.000 description 8
• 206010063837 Reperfusion injury Diseases 0.000 description 8
• RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 238000010256 biochemical assay Methods 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 238000012512 characterization method Methods 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 230000002147 killing effect Effects 0.000 description 8
• 239000010410 layer Substances 0.000 description 8
• 235000019198 oils Nutrition 0.000 description 8
• 238000007911 parenteral administration Methods 0.000 description 8
• 230000003389 potentiating effect Effects 0.000 description 8
• 238000012552 review Methods 0.000 description 8
• 239000000741 silica gel Substances 0.000 description 8
• 229910002027 silica gel Inorganic materials 0.000 description 8
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 238000005406 washing Methods 0.000 description 8
• QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 8
• SZQMTCSQWUYUML-UHFFFAOYSA-N 2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CCC(C(O)=O)NC(=O)OCC1=CC=CC=C1 SZQMTCSQWUYUML-UHFFFAOYSA-N 0.000 description 7
• SZCPTRGBOVXVCA-UHFFFAOYSA-N 2-amino-6-chlorobenzoic acid Chemical compound NC1=CC=CC(Cl)=C1C(O)=O SZCPTRGBOVXVCA-UHFFFAOYSA-N 0.000 description 7
• PMMZQALLFLKUOM-UHFFFAOYSA-N 3-[2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-4-oxoquinazolin-3-yl]benzamide Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C(N)=O)=C1 PMMZQALLFLKUOM-UHFFFAOYSA-N 0.000 description 7
• UNRIYCIDCQDGQE-UHFFFAOYSA-N 6-chloro-2-fluoro-7h-purine Chemical compound FC1=NC(Cl)=C2NC=NC2=N1 UNRIYCIDCQDGQE-UHFFFAOYSA-N 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
• 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 7
• 101710096503 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 7
• 239000000427 antigen Substances 0.000 description 7
• 102000036639 antigens Human genes 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 230000027455 binding Effects 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 238000001914 filtration Methods 0.000 description 7
• 125000001153 fluoro group Chemical group F* 0.000 description 7
• 210000003630 histaminocyte Anatomy 0.000 description 7
• 230000002757 inflammatory effect Effects 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
• 150000003905 phosphatidylinositols Chemical class 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• 229920006395 saturated elastomer Polymers 0.000 description 7
• 235000017557 sodium bicarbonate Nutrition 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 241000701447 unidentified baculovirus Species 0.000 description 7
• PNFVIPIQXAIUAY-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC[C@@H](C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-LURJTMIESA-N 0.000 description 6
• WVRQOFJTDBUJLF-UHFFFAOYSA-N 3-(3-ethynylphenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C#C)=C1 WVRQOFJTDBUJLF-UHFFFAOYSA-N 0.000 description 6
• IHHKTIKNEDOMIK-UHFFFAOYSA-N 3-(morpholin-4-ylmethyl)aniline Chemical compound NC1=CC=CC(CN2CCOCC2)=C1 IHHKTIKNEDOMIK-UHFFFAOYSA-N 0.000 description 6
• BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 6
• BLQKRXSSJCYTKV-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 BLQKRXSSJCYTKV-UHFFFAOYSA-N 0.000 description 6
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• 239000012981 Hank's balanced salt solution Substances 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 6
• 241000124008 Mammalia Species 0.000 description 6
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
• 239000013543 active substance Substances 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 238000000423 cell based assay Methods 0.000 description 6
• 230000003399 chemotactic effect Effects 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 229940125758 compound 15 Drugs 0.000 description 6
• 238000001816 cooling Methods 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 231100000673 dose–response relationship Toxicity 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 238000001035 drying Methods 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
• IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 6
• 230000016784 immunoglobulin production Effects 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 239000002244 precipitate Substances 0.000 description 6
• 238000003375 selectivity assay Methods 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
• QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 5
• HOGPKNMMOUTFJO-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-6-nitrobenzoic acid Chemical compound C1=CC=C([N+]([O-])=O)C(C(=O)O)=C1CN1CCOCC1 HOGPKNMMOUTFJO-UHFFFAOYSA-N 0.000 description 5
• WNHDEZOYHRMSQG-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(F)C=CC=C1F WNHDEZOYHRMSQG-UHFFFAOYSA-N 0.000 description 5
• IIPMNWKOHFBSNF-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-3-(3-morpholin-4-ylphenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C(C=1)=CC=CC=1N1CCOCC1 IIPMNWKOHFBSNF-UHFFFAOYSA-N 0.000 description 5
• KPJVRVKIIWLHTG-UHFFFAOYSA-N 2-[4-(diethylamino)-1-(7h-purin-6-ylamino)butyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CCCN(CC)CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 KPJVRVKIIWLHTG-UHFFFAOYSA-N 0.000 description 5
• KQOIBXZRCYFZSO-UHFFFAOYSA-N 3,5-difluoroaniline Chemical compound NC1=CC(F)=CC(F)=C1 KQOIBXZRCYFZSO-UHFFFAOYSA-N 0.000 description 5
• PPGLBOHLGNCPTB-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(F)C=CC=C1F PPGLBOHLGNCPTB-UHFFFAOYSA-N 0.000 description 5
• WWEWDONXTAIVOB-UHFFFAOYSA-N 3-[2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-4-oxoquinazolin-3-yl]benzonitrile Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C#N)=C1 WWEWDONXTAIVOB-UHFFFAOYSA-N 0.000 description 5
• JZSLCEVYPKJSLX-UHFFFAOYSA-N 3-[3-(2-methoxyethoxy)phenyl]-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound COCCOC1=CC=CC(N2C(C3=C(C)C=CC=C3N=C2C(C)NC=2C=3N=CNC=3N=CN=2)=O)=C1 JZSLCEVYPKJSLX-UHFFFAOYSA-N 0.000 description 5
• LKEKTRKCWPPGRA-UHFFFAOYSA-N 3-[3-[2-(dimethylamino)ethoxy]phenyl]-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(OCCN(C)C)=C1 LKEKTRKCWPPGRA-UHFFFAOYSA-N 0.000 description 5
• QCQVYTDXECHIQN-UHFFFAOYSA-N 3-[5-methyl-4-oxo-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-3-yl]benzamide Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C(N)=O)=C1 QCQVYTDXECHIQN-UHFFFAOYSA-N 0.000 description 5
• GBHQQXBDLYGRRO-UHFFFAOYSA-N 3-[5-methyl-4-oxo-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-3-yl]benzonitrile Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C#N)=C1 GBHQQXBDLYGRRO-UHFFFAOYSA-N 0.000 description 5
• FPQMGQZTBWIHDN-UHFFFAOYSA-N 5-fluoroanthranilic acid Chemical compound NC1=CC=C(F)C=C1C(O)=O FPQMGQZTBWIHDN-UHFFFAOYSA-N 0.000 description 5
• 208000006386 Bone Resorption Diseases 0.000 description 5
• 241000283707 Capra Species 0.000 description 5
• 101001024630 Drosophila melanogaster RNA cytidine acetyltransferase Proteins 0.000 description 5
• 101000652705 Drosophila melanogaster Transcription initiation factor TFIID subunit 4 Proteins 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 102000000588 Interleukin-2 Human genes 0.000 description 5
• 108010002350 Interleukin-2 Proteins 0.000 description 5
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 229910003827 NRaRb Inorganic materials 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• 239000012828 PI3K inhibitor Substances 0.000 description 5
• 206010057249 Phagocytosis Diseases 0.000 description 5
• 101000996915 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleoporin NSP1 Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 5
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
• 208000027418 Wounds and injury Diseases 0.000 description 5
• SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 230000024279 bone resorption Effects 0.000 description 5
• 229940098773 bovine serum albumin Drugs 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 239000012267 brine Substances 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 150000001768 cations Chemical class 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 125000001309 chloro group Chemical group Cl* 0.000 description 5
• 229940125773 compound 10 Drugs 0.000 description 5
• 229940127271 compound 49 Drugs 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 238000001704 evaporation Methods 0.000 description 5
• 230000008020 evaporation Effects 0.000 description 5
• 239000012091 fetal bovine serum Substances 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
• 208000032839 leukemia Diseases 0.000 description 5
• 150000002632 lipids Chemical class 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 229930014626 natural product Natural products 0.000 description 5
• 230000008782 phagocytosis Effects 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 239000002953 phosphate buffered saline Substances 0.000 description 5
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 5
• 239000012453 solvate Substances 0.000 description 5
• 239000003381 stabilizer Substances 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 230000000451 tissue damage Effects 0.000 description 5
• 231100000827 tissue damage Toxicity 0.000 description 5
• 231100000419 toxicity Toxicity 0.000 description 5
• 230000001988 toxicity Effects 0.000 description 5
• 238000012384 transportation and delivery Methods 0.000 description 5
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
• OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 4
• UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 4
• ODUZJBKKYBQIBX-UHFFFAOYSA-N 2,6-difluoroaniline Chemical compound NC1=C(F)C=CC=C1F ODUZJBKKYBQIBX-UHFFFAOYSA-N 0.000 description 4
• YVKAHOVKWWEEQC-UHFFFAOYSA-N 2-(1-aminoethyl)-3-(3-hydroxyphenyl)-5-methylquinazolin-4-one Chemical compound CC(N)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(O)=C1 YVKAHOVKWWEEQC-UHFFFAOYSA-N 0.000 description 4
• UGTRVMAQBPWFBM-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)-6-nitro-n-phenylbenzamide Chemical compound C=1C=CC=CC=1NC(=O)C=1C([N+](=O)[O-])=CC=CC=1CN1CCOCC1 UGTRVMAQBPWFBM-UHFFFAOYSA-N 0.000 description 4
• RIMYZARSUQSMGM-UHFFFAOYSA-N 2-[(6-bromopurin-9-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=NC2=C1Br RIMYZARSUQSMGM-UHFFFAOYSA-N 0.000 description 4
• UKSNGHQVUXARTP-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3-ethynylphenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C#C)=C1 UKSNGHQVUXARTP-UHFFFAOYSA-N 0.000 description 4
• JZQOKUBPKUKIMR-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-[3-(2-methoxyethoxy)phenyl]-5-methylquinazolin-4-one Chemical compound COCCOC1=CC=CC(N2C(C3=C(C)C=CC=C3N=C2C(C)NC=2C=3N=CNC=3N=C(N)N=2)=O)=C1 JZQOKUBPKUKIMR-UHFFFAOYSA-N 0.000 description 4
• SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 4
• JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 4
• RQXYSNWMUKZOEX-UHFFFAOYSA-N 3-phenyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 RQXYSNWMUKZOEX-UHFFFAOYSA-N 0.000 description 4
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
• MORMTYLSFKKOGP-UHFFFAOYSA-N 4-[(3-nitrophenyl)methyl]morpholine Chemical compound [O-][N+](=O)C1=CC=CC(CN2CCOCC2)=C1 MORMTYLSFKKOGP-UHFFFAOYSA-N 0.000 description 4
• OOBFPXOXHUBRDN-UHFFFAOYSA-N 4-chloro-5-fluoro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(F)=CNC2=N1 OOBFPXOXHUBRDN-UHFFFAOYSA-N 0.000 description 4
• KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 4
• VGCCPKUHSJUZGV-UHFFFAOYSA-N 5-chloro-3-(3,5-difluorophenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC(F)=CC(F)=C1 VGCCPKUHSJUZGV-UHFFFAOYSA-N 0.000 description 4
• YAFJINVASNOMDF-UHFFFAOYSA-N 5-methyl-3-(3-morpholin-4-ylphenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C(C=1)=CC=CC=1N1CCOCC1 YAFJINVASNOMDF-UHFFFAOYSA-N 0.000 description 4
• CJILTBVQEPXLIW-UHFFFAOYSA-N 6-fluoro-3-[3-(oxan-4-yloxy)phenyl]-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=C(F)C=C2C(=O)N1C(C=1)=CC=CC=1OC1CCOCC1 CJILTBVQEPXLIW-UHFFFAOYSA-N 0.000 description 4
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 4
• 229940126657 Compound 17 Drugs 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• 108091000080 Phosphotransferase Proteins 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 206010040047 Sepsis Diseases 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• IBALAJDOMVRAIP-UHFFFAOYSA-N [1-[3-methyl-2-(phenylcarbamoyl)phenyl]imino-1-piperidin-1-ylpropan-2-yl] acetate Chemical compound C1CCCCN1C(C(OC(C)=O)C)=NC1=CC=CC(C)=C1C(=O)NC1=CC=CC=C1 IBALAJDOMVRAIP-UHFFFAOYSA-N 0.000 description 4
• 238000002835 absorbance Methods 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 230000001747 exhibiting effect Effects 0.000 description 4
• 210000003714 granulocyte Anatomy 0.000 description 4
• 230000003394 haemopoietic effect Effects 0.000 description 4
• 238000013537 high throughput screening Methods 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• SJJJFLXTGHEZJB-UHFFFAOYSA-N methyl 2-(bromomethyl)-6-nitrobenzoate Chemical compound COC(=O)C1=C(CBr)C=CC=C1[N+]([O-])=O SJJJFLXTGHEZJB-UHFFFAOYSA-N 0.000 description 4
• AOXPHVNMBPFOFS-UHFFFAOYSA-N methyl 2-nitrobenzoate Chemical compound COC(=O)C1=CC=CC=C1[N+]([O-])=O AOXPHVNMBPFOFS-UHFFFAOYSA-N 0.000 description 4
• PKGGSXFYHSOKMV-UHFFFAOYSA-N n-(2,6-difluorophenyl)-2-methyl-6-nitrobenzamide Chemical compound CC1=CC=CC([N+]([O-])=O)=C1C(=O)NC1=C(F)C=CC=C1F PKGGSXFYHSOKMV-UHFFFAOYSA-N 0.000 description 4
• 230000002093 peripheral effect Effects 0.000 description 4
• 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 4
• 102000020233 phosphotransferase Human genes 0.000 description 4
• 238000013207 serial dilution Methods 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 239000012265 solid product Substances 0.000 description 4
• 239000000600 sorbitol Substances 0.000 description 4
• 230000035886 specific defense system Effects 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
• UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
• VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 3
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
• MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• JDHLOPNMGJXMQH-UHFFFAOYSA-N 1-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)ethyl acetate Chemical compound CC(=O)OC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 JDHLOPNMGJXMQH-UHFFFAOYSA-N 0.000 description 3
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
• QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 3
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
• WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 3
• LMZLRULIVVIDCZ-UHFFFAOYSA-N 2-(1-hydroxyethyl)-5-methyl-3-phenylquinazolin-4-one Chemical compound CC(O)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 LMZLRULIVVIDCZ-UHFFFAOYSA-N 0.000 description 3
• QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 3
• BNMGOWXQUZHWIO-ZDUSSCGKSA-N 2-[(1s)-1-aminopropyl]-5-fluoro-3-phenylquinazolin-4-one Chemical compound CC[C@H](N)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 BNMGOWXQUZHWIO-ZDUSSCGKSA-N 0.000 description 3
• JLFVNJDUQXBVNG-UHFFFAOYSA-N 2-[(6-chloropurin-9-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=NC2=C1Cl JLFVNJDUQXBVNG-UHFFFAOYSA-N 0.000 description 3
• WBZLZNGXQBJHAP-UHFFFAOYSA-N 2-[(benzhydrylideneamino)methyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1CN=C(C=1C=CC=CC=1)C1=CC=CC=C1 WBZLZNGXQBJHAP-UHFFFAOYSA-N 0.000 description 3
• CNQGMFKVXGYINO-UHFFFAOYSA-N 2-[1-(benzhydrylideneamino)but-3-ynyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(CC#C)N=C(C=1C=CC=CC=1)C1=CC=CC=C1 CNQGMFKVXGYINO-UHFFFAOYSA-N 0.000 description 3
• SLDMLCVOQLFNPF-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]-2-hydroxyethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(CO)NC=2C=3N=CNC=3N=C(N)N=2)N1C1=CC=CC=C1 SLDMLCVOQLFNPF-UHFFFAOYSA-N 0.000 description 3
• ZCWNXZOYNVLYDZ-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]butyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CCC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 ZCWNXZOYNVLYDZ-UHFFFAOYSA-N 0.000 description 3
• PNCADCUDOZDISU-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3,5-dichlorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC(Cl)=CC(Cl)=C1 PNCADCUDOZDISU-UHFFFAOYSA-N 0.000 description 3
• GDYNYBDUGKZMOK-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(F)=C1 GDYNYBDUGKZMOK-UHFFFAOYSA-N 0.000 description 3
• WFMBKTUCCMFEPO-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3-fluorophenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC=C2C(=O)N1C1=CC=CC(F)=C1 WFMBKTUCCMFEPO-UHFFFAOYSA-N 0.000 description 3
• WVKKHITVLVFBKE-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-[3-[2-(dimethylamino)ethoxy]phenyl]-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(OCCN(C)C)=C1 WVKKHITVLVFBKE-UHFFFAOYSA-N 0.000 description 3
• WZEGNCLTHHARFT-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-(morpholin-4-ylmethyl)-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C(N(C(=O)C1=2)C=3C=CC=CC=3)=NC1=CC=CC=2CN1CCOCC1 WZEGNCLTHHARFT-UHFFFAOYSA-N 0.000 description 3
• YTXJGWGRBHUZTM-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-chloro-3-(3,5-difluorophenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC(F)=CC(F)=C1 YTXJGWGRBHUZTM-UHFFFAOYSA-N 0.000 description 3
• FXHJBNMLHZYODX-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-3-(3-methylphenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C)=C1 FXHJBNMLHZYODX-UHFFFAOYSA-N 0.000 description 3
• ZXNYQYXHIKMSHP-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-3-[3-(morpholin-4-ylmethyl)phenyl]quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C(C=1)=CC=CC=1CN1CCOCC1 ZXNYQYXHIKMSHP-UHFFFAOYSA-N 0.000 description 3
• MFPSPGGNLXXQQM-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-6-fluoro-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 MFPSPGGNLXXQQM-UHFFFAOYSA-N 0.000 description 3
• NXPCBMADUUVTNZ-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]propyl]-3-(3,5-difluorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC(F)=CC(F)=C1 NXPCBMADUUVTNZ-UHFFFAOYSA-N 0.000 description 3
• YIMJRXNZCUFOIL-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]propyl]-5-chloro-3-(3,5-difluorophenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC(F)=CC(F)=C1 YIMJRXNZCUFOIL-UHFFFAOYSA-N 0.000 description 3
• AZJDVQAOQBEKRR-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]propyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 AZJDVQAOQBEKRR-UHFFFAOYSA-N 0.000 description 3
• NLRFHULOUIWAEY-UHFFFAOYSA-N 2-[1-[(2-fluoro-7h-purin-6-yl)amino]-2-phenylmethoxyethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=C(F)N=1)COCC1=CC=CC=C1 NLRFHULOUIWAEY-UHFFFAOYSA-N 0.000 description 3
• UTEKOXAIFHQDJY-UHFFFAOYSA-N 2-[1-[(2-fluoro-7h-purin-6-yl)amino]ethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound N=1C(F)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 UTEKOXAIFHQDJY-UHFFFAOYSA-N 0.000 description 3
• JOPABZAYPKGITC-UHFFFAOYSA-N 2-[2-hydroxy-1-(7h-purin-6-ylamino)ethyl]-3-phenylquinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CO)C1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 JOPABZAYPKGITC-UHFFFAOYSA-N 0.000 description 3
• BQDUFZKKZSYYSY-UHFFFAOYSA-N 2-[4-amino-1-[(2-amino-7h-purin-6-yl)amino]butyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(CCCN)NC=2C=3N=CNC=3N=C(N)N=2)N1C1=CC=CC=C1 BQDUFZKKZSYYSY-UHFFFAOYSA-N 0.000 description 3
• LCIWSTOHYFXDTF-UHFFFAOYSA-N 2-[[(2-fluoro-7h-purin-6-yl)amino]-phenylmethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=C(F)N=1)C1=CC=CC=C1 LCIWSTOHYFXDTF-UHFFFAOYSA-N 0.000 description 3
• FQKAGCKHAZVARD-UHFFFAOYSA-N 2-amino-6-chloro-n-(3,5-difluorophenyl)benzamide Chemical compound NC1=CC=CC(Cl)=C1C(=O)NC1=CC(F)=CC(F)=C1 FQKAGCKHAZVARD-UHFFFAOYSA-N 0.000 description 3
• FKRARSSOACTEHP-UHFFFAOYSA-N 2-amino-6-methyl-n-phenylbenzamide Chemical compound CC1=CC=CC(N)=C1C(=O)NC1=CC=CC=C1 FKRARSSOACTEHP-UHFFFAOYSA-N 0.000 description 3
• GQVRPSFDUVNMDA-UHFFFAOYSA-N 2-fluoro-6-nitro-n-phenylbenzamide Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1C(=O)NC1=CC=CC=C1 GQVRPSFDUVNMDA-UHFFFAOYSA-N 0.000 description 3
• LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 3
• XLJVEBRFYDUKKP-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(F)C=CC=C1F XLJVEBRFYDUKKP-UHFFFAOYSA-N 0.000 description 3
• OYAYEPIDJGEAAS-UHFFFAOYSA-N 3-(2,6-dimethylphenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(C)C=CC=C1C OYAYEPIDJGEAAS-UHFFFAOYSA-N 0.000 description 3
• NQVAXCCVPUBNJC-UHFFFAOYSA-N 3-(3,5-dichlorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC(Cl)=CC(Cl)=C1 NQVAXCCVPUBNJC-UHFFFAOYSA-N 0.000 description 3
• FZVCYROQZLKMNX-UHFFFAOYSA-N 3-(3,5-difluorophenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC=C2C(=O)N1C1=CC(F)=CC(F)=C1 FZVCYROQZLKMNX-UHFFFAOYSA-N 0.000 description 3
• OWTMTJWDZILAMW-UHFFFAOYSA-N 3-(3,5-difluorophenyl)-6-fluoro-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=C(F)C=C2C(=O)N1C1=CC(F)=CC(F)=C1 OWTMTJWDZILAMW-UHFFFAOYSA-N 0.000 description 3
• MVHWWXZYKQKESM-UHFFFAOYSA-N 3-(3-acetylphenyl)-2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C(C)=O)=C1 MVHWWXZYKQKESM-UHFFFAOYSA-N 0.000 description 3
• WHWZQSDYESIRKH-UHFFFAOYSA-N 3-(3-acetylphenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C(C)=O)=C1 WHWZQSDYESIRKH-UHFFFAOYSA-N 0.000 description 3
• OSJUTODIQCURGT-UHFFFAOYSA-N 3-(3-chlorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(Cl)=C1 OSJUTODIQCURGT-UHFFFAOYSA-N 0.000 description 3
• LDUYIRMWZOSNHS-UHFFFAOYSA-N 3-(3-methoxyphenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound COC1=CC=CC(N2C(C3=C(C)C=CC=C3N=C2C(C)NC=2C=3N=CNC=3N=CN=2)=O)=C1 LDUYIRMWZOSNHS-UHFFFAOYSA-N 0.000 description 3
• GJGHDYMVCHFVCG-UHFFFAOYSA-N 3-(4-fluorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=C(F)C=C1 GJGHDYMVCHFVCG-UHFFFAOYSA-N 0.000 description 3
• WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 3
• IIRQYHDHKBMCRI-UHFFFAOYSA-N 3-[5-methyl-4-oxo-2-[1-[[9-(2-trimethylsilylethoxymethyl)purin-6-yl]amino]ethyl]quinazolin-3-yl]benzonitrile Chemical compound N=1C=NC=2N(COCC[Si](C)(C)C)C=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C#N)=C1 IIRQYHDHKBMCRI-UHFFFAOYSA-N 0.000 description 3
• ROIASNIEFPZNJL-UHFFFAOYSA-N 3-phenyl-2-[1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 ROIASNIEFPZNJL-UHFFFAOYSA-N 0.000 description 3
• GWNLVRMEIXKYLV-UHFFFAOYSA-N 5-(morpholin-4-ylmethyl)-3-phenyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C(N(C(=O)C1=2)C=3C=CC=CC=3)=NC1=CC=CC=2CN1CCOCC1 GWNLVRMEIXKYLV-UHFFFAOYSA-N 0.000 description 3
• XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
• XSSYYHQNXNHAIK-UHFFFAOYSA-N 5-chloro-3-(2,6-difluorophenyl)-2-[1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=C(F)C=CC=C1F XSSYYHQNXNHAIK-UHFFFAOYSA-N 0.000 description 3
• SBLJIOPVIXLQIP-UHFFFAOYSA-N 5-chloro-3-phenyl-2-[1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SBLJIOPVIXLQIP-UHFFFAOYSA-N 0.000 description 3
• BVUBLIHUYSRSFE-UHFFFAOYSA-N 5-fluoro-3-phenyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 BVUBLIHUYSRSFE-UHFFFAOYSA-N 0.000 description 3
• QRRSIFNWHCKMSW-UHFFFAOYSA-N 5-methyl-2-nitrobenzoic acid Chemical compound CC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 QRRSIFNWHCKMSW-UHFFFAOYSA-N 0.000 description 3
• UDQVDQJVNDLJAA-UHFFFAOYSA-N 5-methyl-3-(3-methylphenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C)=C1 UDQVDQJVNDLJAA-UHFFFAOYSA-N 0.000 description 3
• DDVUNCJOFGNVEQ-UHFFFAOYSA-N 5-methyl-3-(3-prop-2-ynoxyphenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(OCC#C)=C1 DDVUNCJOFGNVEQ-UHFFFAOYSA-N 0.000 description 3
• PFJKYYFKFHTRQY-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 PFJKYYFKFHTRQY-UHFFFAOYSA-N 0.000 description 3
• BYQQTYAGNWPBLO-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[1-(7h-purin-6-yloxy)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1OC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 BYQQTYAGNWPBLO-UHFFFAOYSA-N 0.000 description 3
• DKLNZSQCCOGZBH-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[1-[9-(2-trimethylsilylethoxymethyl)purin-6-yl]oxyethyl]quinazolin-4-one Chemical compound N=1C=NC=2N(COCC[Si](C)(C)C)C=NC=2C=1OC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 DKLNZSQCCOGZBH-UHFFFAOYSA-N 0.000 description 3
• NNOSEZGVRWKINW-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[3,3,3-trifluoro-1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(CC(F)(F)F)NC=2C=3N=CNC=3N=CN=2)N1C1=CC=CC=C1 NNOSEZGVRWKINW-UHFFFAOYSA-N 0.000 description 3
• HAWITXDCGUCXPV-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[phenyl-(7h-purin-6-ylamino)methyl]quinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=CN=1)C1=CC=CC=C1 HAWITXDCGUCXPV-UHFFFAOYSA-N 0.000 description 3
• SJFUIEXXDXFYKG-UHFFFAOYSA-N 6,7-difluoro-3-phenyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC(F)=C(F)C=C2C(=O)N1C1=CC=CC=C1 SJFUIEXXDXFYKG-UHFFFAOYSA-N 0.000 description 3
• ZBHOSYKKCBCKTC-UHFFFAOYSA-N 6-bromo-9-(2-trimethylsilylethoxymethyl)purin-2-amine Chemical compound N1=C(N)N=C2N(COCC[Si](C)(C)C)C=NC2=C1Br ZBHOSYKKCBCKTC-UHFFFAOYSA-N 0.000 description 3
• IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• 206010014561 Emphysema Diseases 0.000 description 3
• 229920001917 Ficoll Polymers 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 102000003923 Protein Kinase C Human genes 0.000 description 3
• 108090000315 Protein Kinase C Proteins 0.000 description 3
• 102000014128 RANK Ligand Human genes 0.000 description 3
• 108010025832 RANK Ligand Proteins 0.000 description 3
• 206010040070 Septic Shock Diseases 0.000 description 3
• 208000006011 Stroke Diseases 0.000 description 3
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
• VDEKDQAIFVSFBP-UHFFFAOYSA-N [1-[3-methyl-2-(phenylcarbamoyl)anilino]-1-oxopropan-2-yl] acetate Chemical compound CC(=O)OC(C)C(=O)NC1=CC=CC(C)=C1C(=O)NC1=CC=CC=C1 VDEKDQAIFVSFBP-UHFFFAOYSA-N 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• IYFPPWNDZXLYHY-UHFFFAOYSA-N benzyl n-[1-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamate Chemical compound N=1C2=CC=CC(C)=C2C(=O)N(C=2C=CC=CC=2)C=1C(CC)NC(=O)OCC1=CC=CC=C1 IYFPPWNDZXLYHY-UHFFFAOYSA-N 0.000 description 3
• AGDPMEWFXSMLKT-UHFFFAOYSA-N benzyl n-[4-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)-4-(7h-purin-6-ylamino)butyl]carbamate Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=CN=1)CCCNC(=O)OCC1=CC=CC=C1 AGDPMEWFXSMLKT-UHFFFAOYSA-N 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 150000001649 bromium compounds Chemical class 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 229940125797 compound 12 Drugs 0.000 description 3
• 229940126142 compound 16 Drugs 0.000 description 3
• 229940125782 compound 2 Drugs 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 239000013058 crude material Substances 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 210000003038 endothelium Anatomy 0.000 description 3
• GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 239000011630 iodine Substances 0.000 description 3
• 229910052749 magnesium Inorganic materials 0.000 description 3
• JOPMPYXEOLUEKZ-UHFFFAOYSA-N methyl 2-(morpholin-4-ylmethyl)-6-nitrobenzoate Chemical compound C1=CC=C([N+]([O-])=O)C(C(=O)OC)=C1CN1CCOCC1 JOPMPYXEOLUEKZ-UHFFFAOYSA-N 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 239000002808 molecular sieve Substances 0.000 description 3
• 208000010125 myocardial infarction Diseases 0.000 description 3
• 229910052759 nickel Inorganic materials 0.000 description 3
• 230000035781 nonspecific defense system Effects 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 108091033319 polynucleotide Proteins 0.000 description 3
• 102000040430 polynucleotide Human genes 0.000 description 3
• 239000002157 polynucleotide Substances 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 230000010410 reperfusion Effects 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 239000000377 silicon dioxide Substances 0.000 description 3
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
• KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• QFOZQYXYXFTQNB-INIZCTEOSA-N tert-butyl n-[(1s)-1-(5-fluoro-4-oxo-3-phenylquinazolin-2-yl)propyl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](CC)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 QFOZQYXYXFTQNB-INIZCTEOSA-N 0.000 description 3
• JPHKGGYNRMICTQ-UHFFFAOYSA-N tert-butyl n-[1-[3-chloro-2-[(3,5-difluorophenyl)carbamoyl]anilino]-1-oxopropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)NC1=CC=CC(Cl)=C1C(=O)NC1=CC(F)=CC(F)=C1 JPHKGGYNRMICTQ-UHFFFAOYSA-N 0.000 description 3
• ULNWEQMIDINSRX-UHFFFAOYSA-N tert-butyl n-[1-[5-chloro-4-(3,5-difluorophenyl)imino-3,1-benzoxazin-2-yl]ethyl]carbamate Chemical compound O1C(C(NC(=O)OC(C)(C)C)C)=NC2=CC=CC(Cl)=C2C1=NC1=CC(F)=CC(F)=C1 ULNWEQMIDINSRX-UHFFFAOYSA-N 0.000 description 3
• NNFIUCSBFBELBI-UHFFFAOYSA-N tert-butyl n-[4-amino-1-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)butyl]carbamate Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(CCCN)NC(=O)OC(C)(C)C)N1C1=CC=CC=C1 NNFIUCSBFBELBI-UHFFFAOYSA-N 0.000 description 3
• PQMFNJOJFGEBLR-JOCHJYFZSA-N tert-butyl n-[[(1s)-1-(2-fluoro-6-nitrobenzoyl)cyclohexa-2,4-dien-1-yl]carbamoyl]-n-propylcarbamate Chemical compound FC=1C=CC=C([N+]([O-])=O)C=1C(=O)[C@]1(NC(=O)N(CCC)C(=O)OC(C)(C)C)CC=CC=C1 PQMFNJOJFGEBLR-JOCHJYFZSA-N 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 238000003828 vacuum filtration Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
• ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
• OYARCVZBPRJTQS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(phenylmethoxycarbonylamino)pentanoate Chemical compound O=C1CCC(=O)N1OC(=O)C(CCC)NC(=O)OCC1=CC=CC=C1 OYARCVZBPRJTQS-UHFFFAOYSA-N 0.000 description 2
• JPEHHKZULQJYEW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetate Chemical compound C=1C=CC=CC=1C(NC(=O)OC(C)(C)C)C(=O)ON1C(=O)CCC1=O JPEHHKZULQJYEW-UHFFFAOYSA-N 0.000 description 2
• HLTFLYMXIANSTL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)NC(CC)C(=O)ON1C(=O)CCC1=O HLTFLYMXIANSTL-UHFFFAOYSA-N 0.000 description 2
• HSJCWCOSSJNXAN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[(2-methylpropan-2-yl)oxy]-2-(phenylmethoxycarbonylamino)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)C(COC(C)(C)C)NC(=O)OCC1=CC=CC=C1 HSJCWCOSSJNXAN-UHFFFAOYSA-N 0.000 description 2
• IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
• YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 2
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
• STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
• UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
• OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
• YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
• STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
• VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
• DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
• KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 2
• FHECQGWITSJOHM-UHFFFAOYSA-N 1-(5-methyl-4-phenylimino-3,1-benzoxazin-2-yl)ethyl acetate Chemical compound O1C(C(OC(C)=O)C)=NC2=CC=CC(C)=C2C1=NC1=CC=CC=C1 FHECQGWITSJOHM-UHFFFAOYSA-N 0.000 description 2
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
• UFFBMTHBGFGIHF-UHFFFAOYSA-N 2,6-dimethylaniline Chemical compound CC1=CC=CC(C)=C1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 description 2
• FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
• CKMVNSMILBEBSA-UHFFFAOYSA-N 2-(1-aminobut-3-ynyl)-5-methyl-3-phenylquinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(N)CC#C)N1C1=CC=CC=C1 CKMVNSMILBEBSA-UHFFFAOYSA-N 0.000 description 2
• FCMNWZJOJHTEFB-UHFFFAOYSA-N 2-(1-aminoethyl)-5-chloro-3-(3,5-difluorophenyl)quinazolin-4-one Chemical compound CC(N)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC(F)=CC(F)=C1 FCMNWZJOJHTEFB-UHFFFAOYSA-N 0.000 description 2
• VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
• CDAZMERIMYLZEM-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]-2-phenylmethoxyethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=C(N)N=1)COCC1=CC=CC=C1 CDAZMERIMYLZEM-UHFFFAOYSA-N 0.000 description 2
• ZNGXEUZHTWREBI-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3-methoxyphenyl)-5-methylquinazolin-4-one Chemical compound COC1=CC=CC(N2C(C3=C(C)C=CC=C3N=C2C(C)NC=2C=3N=CNC=3N=C(N)N=2)=O)=C1 ZNGXEUZHTWREBI-UHFFFAOYSA-N 0.000 description 2
• OIQDSEBHTPNVKA-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-[3-(cyclopropylmethoxy)phenyl]-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C(C=1)=CC=CC=1OCC1CC1 OIQDSEBHTPNVKA-UHFFFAOYSA-N 0.000 description 2
• ZLBARTYCUSIJFW-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-3-(3-prop-2-ynoxyphenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(OCC#C)=C1 ZLBARTYCUSIJFW-UHFFFAOYSA-N 0.000 description 2
• UKNAWSLOAPCMMR-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]propyl]-3-(2,6-difluorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(F)C=CC=C1F UKNAWSLOAPCMMR-UHFFFAOYSA-N 0.000 description 2
• ZPNXUVDZSGLJTA-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]propyl]-5-chloro-3-(2,6-difluorophenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=C(F)C=CC=C1F ZPNXUVDZSGLJTA-UHFFFAOYSA-N 0.000 description 2
• LMEDSYXNSPVVDX-UHFFFAOYSA-N 2-[1-amino-4-(diethylamino)butyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound CCN(CC)CCCC(N)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 LMEDSYXNSPVVDX-UHFFFAOYSA-N 0.000 description 2
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
• ZZOYGUKXZACGFU-UHFFFAOYSA-N 2-[[(2-amino-7h-purin-6-yl)amino]-phenylmethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=C(N)N=1)C1=CC=CC=C1 ZZOYGUKXZACGFU-UHFFFAOYSA-N 0.000 description 2
• FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 2
• PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 2
• VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
• NBUUUJWWOARGNW-UHFFFAOYSA-N 2-amino-5-methylbenzoic acid Chemical compound CC1=CC=C(N)C(C(O)=O)=C1 NBUUUJWWOARGNW-UHFFFAOYSA-N 0.000 description 2
• RWSFZKWMVWPDGZ-UHFFFAOYSA-N 2-amino-6-fluorobenzoic acid Chemical compound NC1=CC=CC(F)=C1C(O)=O RWSFZKWMVWPDGZ-UHFFFAOYSA-N 0.000 description 2
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
• NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
• JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
• DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 2
• HRORNJNAUXHWIP-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(Cl)C=CC=C1Cl HRORNJNAUXHWIP-UHFFFAOYSA-N 0.000 description 2
• JKLTXGVJCLPSGW-NSHDSACASA-N 3-(2,6-difluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=CC=C2C(=O)N1C1=C(F)C=CC=C1F JKLTXGVJCLPSGW-NSHDSACASA-N 0.000 description 2
• PPGLBOHLGNCPTB-LBPRGKRZSA-N 3-(2,6-difluorophenyl)-5-methyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=CC(C)=C2C(=O)N1C1=C(F)C=CC=C1F PPGLBOHLGNCPTB-LBPRGKRZSA-N 0.000 description 2
• PQZIPKRLIODVNY-LBPRGKRZSA-N 3-(3,5-difluorophenyl)-5-methyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=CC(C)=C2C(=O)N1C1=CC(F)=CC(F)=C1 PQZIPKRLIODVNY-LBPRGKRZSA-N 0.000 description 2
• RATYHMNWOPJSLV-LBPRGKRZSA-N 3-(3-fluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=CC=C2C(=O)N1C1=CC=CC(F)=C1 RATYHMNWOPJSLV-LBPRGKRZSA-N 0.000 description 2
• JRFQJDZTCBKKQW-UHFFFAOYSA-N 3-(3-methoxyphenyl)-5-methyl-2-[1-[[9-(2-trimethylsilylethoxymethyl)purin-6-yl]amino]ethyl]quinazolin-4-one Chemical compound COC1=CC=CC(N2C(C3=C(C)C=CC=C3N=C2C(C)NC=2C=3N=CN(COCC[Si](C)(C)C)C=3N=CN=2)=O)=C1 JRFQJDZTCBKKQW-UHFFFAOYSA-N 0.000 description 2
• NDVZEDSSAHZLFZ-UHFFFAOYSA-N 3-(4-fluorophenyl)-2-[1-[(2-fluoro-7h-purin-6-yl)amino]ethyl]-5-methylquinazolin-4-one Chemical compound N=1C(F)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=C(F)C=C1 NDVZEDSSAHZLFZ-UHFFFAOYSA-N 0.000 description 2
• FXOJAMTZCTYATB-UHFFFAOYSA-N 3-(4-fluorophenyl)-5-methyl-2-[1-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=CC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=C(F)C=C1 FXOJAMTZCTYATB-UHFFFAOYSA-N 0.000 description 2
• QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
• JNYDLASDGUBZDL-UHFFFAOYSA-N 3-[5-methyl-4-oxo-2-[1-[[9-(2-trimethylsilylethoxymethyl)purin-6-yl]amino]ethyl]quinazolin-3-yl]benzamide Chemical compound N=1C=NC=2N(COCC[Si](C)(C)C)C=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(C(N)=O)=C1 JNYDLASDGUBZDL-UHFFFAOYSA-N 0.000 description 2
• XBZVPWIDTDAKDL-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxyaniline Chemical compound CC(C)(C)[Si](C)(C)OC1=CC=CC(N)=C1 XBZVPWIDTDAKDL-UHFFFAOYSA-N 0.000 description 2
• RQXYSNWMUKZOEX-ZDUSSCGKSA-N 3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 RQXYSNWMUKZOEX-ZDUSSCGKSA-N 0.000 description 2
• ZWGYQDHFRIIWAG-UHFFFAOYSA-N 3-phenyl-2-[1-(7h-purin-6-ylamino)ethyl]-5-(trifluoromethyl)quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C(F)(F)F)=C2C(=O)N1C1=CC=CC=C1 ZWGYQDHFRIIWAG-UHFFFAOYSA-N 0.000 description 2
• WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 2
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
• DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
• VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 2
• OXLMTRZWMHIZBY-UHFFFAOYSA-N 5-bromo-4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(Br)=CN2 OXLMTRZWMHIZBY-UHFFFAOYSA-N 0.000 description 2
• TWLUHIZKDUPYPV-HNNXBMFYSA-N 5-chloro-3-(3,5-difluorophenyl)-2-[(1s)-1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC(F)=CC(F)=C1 TWLUHIZKDUPYPV-HNNXBMFYSA-N 0.000 description 2
• KRVCGGIFARSQAM-NSHDSACASA-N 5-fluoro-2-[(1s)-1-[(2-fluoro-7h-purin-6-yl)amino]ethyl]-3-phenylquinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=C(F)N=2)C)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 KRVCGGIFARSQAM-NSHDSACASA-N 0.000 description 2
• PBLLHXQMLJOFJL-UHFFFAOYSA-N 5-methyl-2-[2-[(2-methylpropan-2-yl)oxy]-1-(7h-purin-6-ylamino)ethyl]-3-phenylquinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(COC(C)(C)C)NC=2C=3N=CNC=3N=CN=2)N1C1=CC=CC=C1 PBLLHXQMLJOFJL-UHFFFAOYSA-N 0.000 description 2
• JJMSXUZXVOKYQV-UHFFFAOYSA-N 5-methyl-3-[3-(oxan-4-yloxy)phenyl]-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C(C=1)=CC=CC=1OC1CCOCC1 JJMSXUZXVOKYQV-UHFFFAOYSA-N 0.000 description 2
• IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 2
• RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
• GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 2
• DOCINCLJNAXZQF-UHFFFAOYSA-N 6-fluoro-3-phenyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-UHFFFAOYSA-N 0.000 description 2
• HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 2
• XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
• UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 2
• PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 108091007958 Class I PI3Ks Proteins 0.000 description 2
• 229940126639 Compound 33 Drugs 0.000 description 2
• 229940127007 Compound 39 Drugs 0.000 description 2
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
• 102000018832 Cytochromes Human genes 0.000 description 2
• 108010052832 Cytochromes Proteins 0.000 description 2
• 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 2
• 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 2
• 206010051392 Diapedesis Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 241000283074 Equus asinus Species 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 208000009329 Graft vs Host Disease Diseases 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
• LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 2
• AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 2
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
• POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 2
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
• QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 102000004264 Osteopontin Human genes 0.000 description 2
• 108010081689 Osteopontin Proteins 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• UBXIJOJXUFYNRG-RJKBCLGNSA-N PIP[3'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(O)(O)=O)C1O UBXIJOJXUFYNRG-RJKBCLGNSA-N 0.000 description 2
• WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
• 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
• PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• 241000191967 Staphylococcus aureus Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• 102000019197 Superoxide Dismutase Human genes 0.000 description 2
• 108010012715 Superoxide dismutase Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
• IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 2
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
• PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
• SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 229960000583 acetic acid Drugs 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229910052783 alkali metal Inorganic materials 0.000 description 2
• 150000001340 alkali metals Chemical class 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• 208000002205 allergic conjunctivitis Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 230000003281 allosteric effect Effects 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000002917 arthritic effect Effects 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
• GVLCWEKXJNAJCN-UHFFFAOYSA-N benzyl n-[5-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)-5-(7h-purin-6-ylamino)pentyl]carbamate Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=CN=1)CCCCNC(=O)OCC1=CC=CC=C1 GVLCWEKXJNAJCN-UHFFFAOYSA-N 0.000 description 2
• ARACCPVGOIGBKM-UHFFFAOYSA-N benzyl n-[5-[(2-amino-7h-purin-6-yl)amino]-5-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)pentyl]carbamate Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=C(N)N=1)CCCCNC(=O)OCC1=CC=CC=C1 ARACCPVGOIGBKM-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical group OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 230000035605 chemotaxis Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 229940125904 compound 1 Drugs 0.000 description 2
• 229940125810 compound 20 Drugs 0.000 description 2
• 229940126086 compound 21 Drugs 0.000 description 2
• 229940126208 compound 22 Drugs 0.000 description 2
• 229940125833 compound 23 Drugs 0.000 description 2
• 229940125961 compound 24 Drugs 0.000 description 2
• 229940125846 compound 25 Drugs 0.000 description 2
• 229940125851 compound 27 Drugs 0.000 description 2
• 229940127204 compound 29 Drugs 0.000 description 2
• 229940126214 compound 3 Drugs 0.000 description 2
• 229940125877 compound 31 Drugs 0.000 description 2
• 229940125878 compound 36 Drugs 0.000 description 2
• 229940125807 compound 37 Drugs 0.000 description 2
• 229940127573 compound 38 Drugs 0.000 description 2
• 229940125936 compound 42 Drugs 0.000 description 2
• 229940125844 compound 46 Drugs 0.000 description 2
• 229940125898 compound 5 Drugs 0.000 description 2
• 229940126545 compound 53 Drugs 0.000 description 2
• 229940127113 compound 57 Drugs 0.000 description 2
• 229940125900 compound 59 Drugs 0.000 description 2
• 229940126179 compound 72 Drugs 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 210000004268 dentin Anatomy 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 238000000855 fermentation Methods 0.000 description 2
• 230000004151 fermentation Effects 0.000 description 2
• 239000012065 filter cake Substances 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 208000024908 graft versus host disease Diseases 0.000 description 2
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 230000004941 influx Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 150000004694 iodide salts Chemical class 0.000 description 2
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000003563 lymphoid tissue Anatomy 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 229960004452 methionine Drugs 0.000 description 2
• 208000037890 multiple organ injury Diseases 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 2
• YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 2
• LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 2
• 210000004897 n-terminal region Anatomy 0.000 description 2
• IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
• 210000000944 nerve tissue Anatomy 0.000 description 2
• 230000011242 neutrophil chemotaxis Effects 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• 230000003204 osmotic effect Effects 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 208000013223 septicemia Diseases 0.000 description 2
• 208000017520 skin disease Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• 229910000104 sodium hydride Inorganic materials 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 230000004960 subcellular localization Effects 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• PNLIDALTIVVHRO-UHFFFAOYSA-N tert-butyl n-[4-(diethylamino)-1-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)butyl]carbamate Chemical compound CCN(CC)CCCC(NC(=O)OC(C)(C)C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 PNLIDALTIVVHRO-UHFFFAOYSA-N 0.000 description 2
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• 229940126585 therapeutic drug Drugs 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
• 238000001665 trituration Methods 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• COMUWNFVTWKSDT-ZETCQYMHSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C)C(=O)ON1C(=O)CCC1=O COMUWNFVTWKSDT-ZETCQYMHSA-N 0.000 description 1
• YWLICOCXPNQJPC-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)C(NC(=O)OC(C)(C)C)CCCCNC(=O)OCC1=CC=CC=C1 YWLICOCXPNQJPC-UHFFFAOYSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
• SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
• DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
• APGGSERFJKEWFG-UHFFFAOYSA-N 1-(chloromethyl)-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(CCl)=C1 APGGSERFJKEWFG-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• DICWIJISMKZDDY-UHFFFAOYSA-N 1-o-tert-butyl 2-o-(2,5-dioxopyrrolidin-1-yl) pyrrolidine-1,2-dicarboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1C(=O)ON1C(=O)CCC1=O DICWIJISMKZDDY-UHFFFAOYSA-N 0.000 description 1
• CCXSGQZMYLXTOI-UHFFFAOYSA-N 13506-76-8 Chemical compound CC1=CC=CC([N+]([O-])=O)=C1C(O)=O CCXSGQZMYLXTOI-UHFFFAOYSA-N 0.000 description 1
• SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 description 1
• LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
• BDHUTRNYBGWPBL-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CCCCNC(=O)OCC1=CC=CC=C1 BDHUTRNYBGWPBL-UHFFFAOYSA-N 0.000 description 1
• PNFVIPIQXAIUAY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CCC(C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-UHFFFAOYSA-N 0.000 description 1
• PHJVUDSABXTRJT-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(2,6-dichlorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(Cl)C=CC=C1Cl PHJVUDSABXTRJT-UHFFFAOYSA-N 0.000 description 1
• ACHZECPYWSOKFW-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(2,6-difluorophenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC=C2C(=O)N1C1=C(F)C=CC=C1F ACHZECPYWSOKFW-UHFFFAOYSA-N 0.000 description 1
• SGXCCFDXBHWDOW-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(2,6-dimethylphenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(C)C=CC=C1C SGXCCFDXBHWDOW-UHFFFAOYSA-N 0.000 description 1
• PASGOJBXXWPFTB-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3,5-difluorophenyl)quinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC=C2C(=O)N1C1=CC(F)=CC(F)=C1 PASGOJBXXWPFTB-UHFFFAOYSA-N 0.000 description 1
• SJZXPPGZMUUFGM-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(3-chlorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(Cl)=C1 SJZXPPGZMUUFGM-UHFFFAOYSA-N 0.000 description 1
• DCJNQEWLRZIHIW-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-3-(4-fluorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=C(F)C=C1 DCJNQEWLRZIHIW-UHFFFAOYSA-N 0.000 description 1
• PRYSURKSDQTXSV-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-chloro-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 PRYSURKSDQTXSV-UHFFFAOYSA-N 0.000 description 1
• PDROOIFXUNZFRH-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]ethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 PDROOIFXUNZFRH-UHFFFAOYSA-N 0.000 description 1
• JWWPDGRIJLKGBA-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]propyl]-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC=C2C(=O)N1C1=CC=CC=C1 JWWPDGRIJLKGBA-UHFFFAOYSA-N 0.000 description 1
• GCDONBGYGCKAKQ-UHFFFAOYSA-N 2-[1-[(2-amino-7h-purin-6-yl)amino]propyl]-5-chloro-3-phenylquinazolin-4-one Chemical compound N=1C(N)=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 GCDONBGYGCKAKQ-UHFFFAOYSA-N 0.000 description 1
• VNFFZGAROXAZHS-UHFFFAOYSA-N 2-[1-[(5-bromo-7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-(3-fluorophenyl)-5-methylquinazolin-4-one Chemical compound N=1C=NC=2NC=C(Br)C=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(F)=C1 VNFFZGAROXAZHS-UHFFFAOYSA-N 0.000 description 1
• KXMCYBQGKGSYAS-UHFFFAOYSA-N 2-[1-[(5-bromo-7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound N=1C=NC=2NC=C(Br)C=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 KXMCYBQGKGSYAS-UHFFFAOYSA-N 0.000 description 1
• ZUXXRIKHBQPWPU-UHFFFAOYSA-N 2-[1-[(5-fluoro-7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound N=1C=NC=2NC=C(F)C=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 ZUXXRIKHBQPWPU-UHFFFAOYSA-N 0.000 description 1
• YKQCYPSXAHEVNW-UHFFFAOYSA-N 2-[2-hydroxy-1-(7h-purin-6-ylamino)ethyl]-5-methyl-3-phenylquinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(CO)NC=2C=3N=CNC=3N=CN=2)N1C1=CC=CC=C1 YKQCYPSXAHEVNW-UHFFFAOYSA-N 0.000 description 1
• DGOZIZVTANAGCA-UHFFFAOYSA-N 2-amino-4,5-difluorobenzoic acid Chemical compound NC1=CC(F)=C(F)C=C1C(O)=O DGOZIZVTANAGCA-UHFFFAOYSA-N 0.000 description 1
• QAVGYOHTBFZWFP-UHFFFAOYSA-N 2-amino-6-(trifluoromethyl)benzoic acid;trihydrate Chemical compound O.O.O.NC1=CC=CC(C(F)(F)F)=C1C(O)=O QAVGYOHTBFZWFP-UHFFFAOYSA-N 0.000 description 1
• JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
• LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
• TZXJJSAQSRHKCZ-UHFFFAOYSA-N 2-methoxyethyl 4-methylbenzenesulfonate Chemical compound COCCOS(=O)(=O)C1=CC=C(C)C=C1 TZXJJSAQSRHKCZ-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• ZKUYSJHXBFFGPU-UHFFFAOYSA-N 2516-95-2 Chemical compound OC(=O)C1=CC(Cl)=CC=C1[N+]([O-])=O ZKUYSJHXBFFGPU-UHFFFAOYSA-N 0.000 description 1
• BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
• JKLTXGVJCLPSGW-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC=C2C(=O)N1C1=C(F)C=CC=C1F JKLTXGVJCLPSGW-UHFFFAOYSA-N 0.000 description 1
• SMAHFHIMVJSUDA-UHFFFAOYSA-N 3-(2,6-difluorophenyl)-2-[1-[(2-fluoro-7h-purin-6-yl)amino]ethyl]-5-methylquinazolin-4-one Chemical compound N=1C(F)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=C(F)C=CC=C1F SMAHFHIMVJSUDA-UHFFFAOYSA-N 0.000 description 1
• PQZIPKRLIODVNY-UHFFFAOYSA-N 3-(3,5-difluorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC(F)=CC(F)=C1 PQZIPKRLIODVNY-UHFFFAOYSA-N 0.000 description 1
• WSFYPJICJPIWOT-UHFFFAOYSA-N 3-(3,5-difluorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC(F)=CC(F)=C1 WSFYPJICJPIWOT-UHFFFAOYSA-N 0.000 description 1
• RATYHMNWOPJSLV-UHFFFAOYSA-N 3-(3-fluorophenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC=C2C(=O)N1C1=CC=CC(F)=C1 RATYHMNWOPJSLV-UHFFFAOYSA-N 0.000 description 1
• WRHVZGNSWBXVHU-UHFFFAOYSA-N 3-(3-fluorophenyl)-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(F)=C1 WRHVZGNSWBXVHU-UHFFFAOYSA-N 0.000 description 1
• KMYJKQBCAOULDQ-UHFFFAOYSA-N 3-(3-fluorophenyl)-5-methyl-2-[1-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=CC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(F)=C1 KMYJKQBCAOULDQ-UHFFFAOYSA-N 0.000 description 1
• ZWCUNRDFHRJPJI-UHFFFAOYSA-N 3-(3-fluorophenyl)-5-methyl-2-[1-[(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=C(C)C=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC(F)=C1 ZWCUNRDFHRJPJI-UHFFFAOYSA-N 0.000 description 1
• PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 1
• AMWKPRGTGKVWJQ-UHFFFAOYSA-N 3-[3-(cyclopropylmethoxy)phenyl]-5-methyl-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C(C=1)=CC=CC=1OCC1CC1 AMWKPRGTGKVWJQ-UHFFFAOYSA-N 0.000 description 1
• CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
• 229940018563 3-aminophenol Drugs 0.000 description 1
• PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
• UCUKFQMRNHNNQY-UHFFFAOYSA-N 4,4,4-trifluoro-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC(F)(F)F UCUKFQMRNHNNQY-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
• GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
• NISJMYPRXDUYTF-UHFFFAOYSA-N 4-chloro-5-methyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(C)=CNC2=N1 NISJMYPRXDUYTF-UHFFFAOYSA-N 0.000 description 1
• LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
• TWLUHIZKDUPYPV-UHFFFAOYSA-N 5-chloro-3-(3,5-difluorophenyl)-2-[1-(7h-purin-6-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CC)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC(F)=CC(F)=C1 TWLUHIZKDUPYPV-UHFFFAOYSA-N 0.000 description 1
• JHOZBIUEXOZLPO-UHFFFAOYSA-N 5-chloro-3-(3-fluorophenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC(F)=C1 JHOZBIUEXOZLPO-UHFFFAOYSA-N 0.000 description 1
• KRVCGGIFARSQAM-UHFFFAOYSA-N 5-fluoro-2-[1-[(2-fluoro-7h-purin-6-yl)amino]ethyl]-3-phenylquinazolin-4-one Chemical compound N=1C(F)=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 KRVCGGIFARSQAM-UHFFFAOYSA-N 0.000 description 1
• GHYZIXDKAPMFCS-UHFFFAOYSA-N 5-fluoro-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1[N+]([O-])=O GHYZIXDKAPMFCS-UHFFFAOYSA-N 0.000 description 1
• PAWCVWLRFLRXBT-UHFFFAOYSA-N 5-methyl-2-[1-[(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]ethyl]-3-phenylquinazolin-4-one Chemical compound N=1C=NC=2NC=C(C)C=2C=1NC(C)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 PAWCVWLRFLRXBT-UHFFFAOYSA-N 0.000 description 1
• DDRKJTIGRSSHGW-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[1-(7h-purin-6-ylamino)but-3-ynyl]quinazolin-4-one Chemical compound O=C1C=2C(C)=CC=CC=2N=C(C(CC#C)NC=2C=3N=CNC=3N=CN=2)N1C1=CC=CC=C1 DDRKJTIGRSSHGW-UHFFFAOYSA-N 0.000 description 1
• NMYUDOXPBINSBT-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[1-(7h-purin-6-ylamino)butyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(CCC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 NMYUDOXPBINSBT-UHFFFAOYSA-N 0.000 description 1
• HHFVVMFMHOIOMG-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[1-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)propyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=CC=2C=1NC(CC)C1=NC2=CC=CC(C)=C2C(=O)N1C1=CC=CC=C1 HHFVVMFMHOIOMG-UHFFFAOYSA-N 0.000 description 1
• RLDJRGMHHAVEHB-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[2-phenylmethoxy-1-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)ethyl]quinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2C=CNC=2N=CN=1)COCC1=CC=CC=C1 RLDJRGMHHAVEHB-UHFFFAOYSA-N 0.000 description 1
• HSTMHTRGCAODQX-UHFFFAOYSA-N 5-methyl-3-phenyl-2-[phenyl-(7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl]quinazolin-4-one Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2C=CNC=2N=CN=1)C1=CC=CC=C1 HSTMHTRGCAODQX-UHFFFAOYSA-N 0.000 description 1
• ZKBQDFAWXLTYKS-UHFFFAOYSA-N 6-Chloro-1H-purine Chemical compound ClC1=NC=NC2=C1NC=N2 ZKBQDFAWXLTYKS-UHFFFAOYSA-N 0.000 description 1
• ORPWNMZXEOGJSM-UHFFFAOYSA-N 6-fluoro-3-(3-fluorophenyl)-2-[1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound N=1C=NC=2NC=NC=2C=1NC(C)C1=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC(F)=C1 ORPWNMZXEOGJSM-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 239000004342 Benzoyl peroxide Substances 0.000 description 1
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 208000025985 Central nervous system inflammatory disease Diseases 0.000 description 1
• 108091007959 Class II PI3Ks Proteins 0.000 description 1
• 108091007963 Class III PI3Ks Proteins 0.000 description 1
• 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 206010014824 Endotoxic shock Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 241000400611 Eucalyptus deanei Species 0.000 description 1
• 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
• 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 102000011652 Formyl peptide receptors Human genes 0.000 description 1
• 108010076288 Formyl peptide receptors Proteins 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 206010018366 Glomerulonephritis acute Diseases 0.000 description 1
• 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
• 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010021138 Hypovolaemic shock Diseases 0.000 description 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• 102000010638 Kinesin Human genes 0.000 description 1
• 108010063296 Kinesin Proteins 0.000 description 1
• FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 229930195722 L-methionine Natural products 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 108090000988 Lysostaphin Proteins 0.000 description 1
• 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
• 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
• 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
• 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• 108010031271 Saccharomyces cerevisiae Proteins Proteins 0.000 description 1
• 208000022639 SchC6pf-Schulz-Passarge syndrome Diseases 0.000 description 1
• 101100391171 Schizosaccharomyces pombe (strain 972 / ATCC 24843) for3 gene Proteins 0.000 description 1
• 208000001364 Schopf-Schulz-Passarge syndrome Diseases 0.000 description 1
• 206010053879 Sepsis syndrome Diseases 0.000 description 1
• 206010049771 Shock haemorrhagic Diseases 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• ALHZEIINTQJLOT-VKHMYHEASA-N [(2s)-1-chloro-1-oxopropan-2-yl] acetate Chemical compound ClC(=O)[C@H](C)OC(C)=O ALHZEIINTQJLOT-VKHMYHEASA-N 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
• 235000019400 benzoyl peroxide Nutrition 0.000 description 1
• ZOABILXFLZGRBD-UHFFFAOYSA-N benzyl n-[4-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)-4-[(2-methylpropan-2-yl)oxycarbonylamino]butyl]carbamate Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC(=O)OC(C)(C)C)CCCNC(=O)OCC1=CC=CC=C1 ZOABILXFLZGRBD-UHFFFAOYSA-N 0.000 description 1
• PTJCGYBEBCIBCO-UHFFFAOYSA-N benzyl n-[4-[(2-amino-7h-purin-6-yl)amino]-4-(5-methyl-4-oxo-3-phenylquinazolin-2-yl)butyl]carbamate Chemical compound C=1C=CC=CC=1N1C(=O)C=2C(C)=CC=CC=2N=C1C(NC=1C=2N=CNC=2N=C(N)N=1)CCCNC(=O)OCC1=CC=CC=C1 PTJCGYBEBCIBCO-UHFFFAOYSA-N 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 206010006451 bronchitis Diseases 0.000 description 1
• 235000010633 broth Nutrition 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 229940126540 compound 41 Drugs 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 230000004940 costimulation Effects 0.000 description 1
• 230000000139 costimulatory effect Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000003182 dose-response assay Methods 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000001210 effect on neutrophils Effects 0.000 description 1
• 238000000921 elemental analysis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 208000003401 eosinophilic granuloma Diseases 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 230000027950 fever generation Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000012997 ficoll-paque Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
• 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000053508 human MARK1 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229940106780 human fibrinogen Drugs 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000006054 immunological memory Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 208000001286 intracranial vasospasm Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 208000011379 keloid formation Diseases 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 239000004922 lacquer Substances 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000001821 langerhans cell Anatomy 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 206010024378 leukocytosis Diseases 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 208000003747 lymphoid leukemia Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
• 210000003574 melanophore Anatomy 0.000 description 1
• 238000002074 melt spinning Methods 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 125000005395 methacrylic acid group Chemical group 0.000 description 1
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 238000010232 migration assay Methods 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000000329 molecular dynamics simulation Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• KUHRIIPUCPOQMQ-UHFFFAOYSA-N n,n-diethyl-3-(ethyliminomethylideneamino)propan-1-amine Chemical compound CCN=C=NCCCN(CC)CC KUHRIIPUCPOQMQ-UHFFFAOYSA-N 0.000 description 1
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 102000027450 oncoproteins Human genes 0.000 description 1
• 108091008819 oncoproteins Proteins 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000008105 phosphatidylcholines Chemical class 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 208000008423 pleurisy Diseases 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229930001119 polyketide Natural products 0.000 description 1
• 125000000830 polyketide group Chemical group 0.000 description 1
• 229930001118 polyketide hybrid Natural products 0.000 description 1
• 125000003308 polyketide hybrid group Chemical group 0.000 description 1
• 229920001843 polymethylhydrosiloxane Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
• CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
• 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
• 238000004080 punching Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 102000016914 ras Proteins Human genes 0.000 description 1
• 108010014186 ras Proteins Proteins 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000003307 reticuloendothelial effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 238000005096 rolling process Methods 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 206010040560 shock Diseases 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• CBHOWTTXCQAOID-UHFFFAOYSA-L sodium ethane formaldehyde mercury(2+) molecular iodine 2-sulfidobenzoate Chemical class [Na+].[Hg++].C[CH2-].II.C=O.[O-]C(=O)c1ccccc1[S-] CBHOWTTXCQAOID-UHFFFAOYSA-L 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 208000020431 spinal cord injury Diseases 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 101150049389 tor2 gene Proteins 0.000 description 1
• 231100000816 toxic dose Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 229940066528 trichloroacetate Drugs 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
• 239000006150 trypticase soy agar Substances 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000007054 vacuolar protein processing Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 201000005539 vernal conjunctivitis Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1